doi:https://doi.org/

References:

Antman E.M., Bennett J.S., Daugherty A., et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634—1642.
Heard K.J. Acetylcysteine for acetaminophen poisoning. N Engl J Med 2008;359:285—292.
Forman J.P., Rimm E.B., Curhan G.C. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007;167:394—399.
Montgomery B. Does paracetamol cause hypertension? BMJ 2008;336:1190—1191.
Chan A.T., Manson J.E., Albert C.M., et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113:1578—1587.
Chalmers J.P., West M.J., Wing L.M., et al. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens A 1984;6:1077—1093.
Radack K.L., Deck C.C., Bloomfield S.S. Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med 1987;107:628—635.
Pavlicevic I., Kuzmanic M., Rumboldt M., Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 2008;15:e372—e382.
Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007;370:2138—2151.
Aw T.J., Haas S.J., Liew D., Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490—496.
Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092—1102.
Aukrust P., Gullestad L., Ueland T., et al. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005;37:74—85.
Forman J.P., Stampfer M.J., Curhan G.C. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46:500—507.
Palmieri E.A., Palmieri V., Innelli P., et al. Aerobic exercise performance correlates with post-ischemic flow-mediated dilation of the brachial artery in young healthy men. Eur J Appl Physiol 2005;94:113—117.
Kurth T., Hennekens C.H., Sturmer T., et al. Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med 2005;165:1903—1909.
Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071—1080.
Wilson S.L, Poulter N.R. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006;24:1457—1469.
Montgomery B.D. Analgesic use and risk of hypertension: concern about bias. Arch Intern Med 2007;167:2368—2369.
Grover S.A., Coupal L., Zowall H. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? Hypertension 2005;45:92—97.
MacMahon S., Peto R., Cutler J., et al. Blood pressure, stroke, and coronary heart disease, part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765—774.
Gurwitz J.H., Avorn J., Bohn R.L., et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994;272:781—786.
Graham G.G., Scott K.F. Mechanism of action of paracetamol. Am J Ther 2005;12:46—55.
Mattammal M.B., Zenser T.V., Brown W.W., et al. Mechanism of inhibition of renal prostaglandin production by acetaminophen. J Pharmacol Exp Ther 1979;210:405—409.
Bippi H., Frolich J.C. Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man. Br J Clin Pharmacol 1990;29:305—310.
Fitzgerald G.A. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709—1711.
Flower R.J., Vane J.R. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972;240:410—411.
Schwab J.M., Schluesener H.J., Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003;361:981—982.
Chandrasekharan N.V., Dai H., Roos K.L., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926—13931.
Hinz B., Cheremina O., Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008;22:383—390.
Bertolini A., Ferrari A., Ottani A., et al. Paracetamol: new vistas of an old drug. CNS Drug Rev 2006;12:250—275.
Flammer A.J., Sudano I., Hermann F., et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008;117:2262—2269.
Hermann F., Forster A., Chenevard R., et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005;45:461—464.
Chenevard R., Hurlimann D., Bechir M., et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405—409.